Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies

NCT05544019 is registered in ClinicalTrials.gov with Schrödinger, Inc. as lead sponsor.

NCT NCT05544019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05544019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies
Lead sponsor
Schrödinger, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 10, 2023
Completion date
November 30, 2027
Enrollment
98 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive large b-cell lymphoma, burkitt lymphoma, chronic lymphocytic leukemia, dlbcl, dlbcl germinal center b-cell type, duodenal-type follicular lymphoma, ebv-positive dlbcl, nos, follicular lymphoma, hhv8-positive dlbcl, nos, high-grade b-cell lymphoma, irf4 gene rearrangement, lymphoplasmacytic lymphoma, malt lymphoma, mantle cell lymphoma, mature b-cell neoplasm, nodal marginal zone lymphoma, non hodgkin lymphoma, pediatric-type follicular lymphoma, plasmablastic lymphoma, primary cutaneous diffuse large b-cell lymphoma, primary cutaneous follicle center lymphoma, primary effusion lymphoma, primary mediastinal large b cell lymphoma, splenic marginal zone lymphoma, t-cell/histiocyte rich lymphoma, waldenstrom macroglobulinemia